Abstract: Background. Treatment for malignant brain gliomas includes surgery, radiation therapy, and chemotherapy with temozolomide. However, this complex treatment does not prevent tumor relapses and progression, which is caused by the activity of tumor cells and a high mutational burden. Researchers are experimenting with different intensity of focused ultrasound (FUS) in the treatment of glioblastoma (GBM). FUS has shown encouraging results in clinical studies.The aim of the study. This review presents brief information on the history of the development of the studied method, the results of its application in experiments and clinical trials, as well as the main possible directions for its implementation in neuro-oncology, in particular, for the treatment of glioblastomas, depending on parameters, including frequency, power, pulse duration and duty cycle.Methods. We carried out an analysis and interpretation of existing publications; for the search, we used the PubMed database and the keywords “focused ultrasound, glioma, HIFU, LIFU”, as well as Yandex and Google search engines and the same keywords in Russian.Results. Low-intensity FUS can be used to temporarily open the blood-brain barrier (BBB), which limits the diffusion of most macromolecules and therapeutic agents into the brain. High-intensity FUS can cause tumor ablation due to a hyperthermic effect, and also stimulate an immunological attack of tumor cells, activate sonosensitizers to exert a cytotoxic effect on tumor tissue, and can increase the sensitivity of tumors to radiation therapy. Histotripsy causes tumor ablation through acoustic cavitation.Conclusion. Focused ultrasound is a promising potential treatment for gliomas. Further study in the form of clinical trials should determine the optimal ultrasound parameters to achieve effective treatment for patients with malignant brain tumors. ; Обоснование. Лечение злокачественных глиом головного мозга включает хирургическое вмешательство, лучевую терапию и химиотерапию с темозоломидом. Однако данное ...
Relation: https://www.actabiomedica.ru/jour/article/view/4603/2736; Parekh K, LeBlang S, Nazarian J, Mueller S, Zacharoulis S, Hynynen K, et al. Past, present and future of focused ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting. Neoplasia. 2023; 37: 100876. doi:10.1016/j.neo.2023.100876; Озеров С.С., Рыжова М.В., Кумирова Э.В. Диффузные опухоли ствола головного мозга у детей. Биология опухоли и надежда на лучший исход. Современное состояние проблемы. Вопросы нейрохирургии им. Н.Н. Бурденко. 2021; 4: 77-86. doi:10.17116/neiro20218504177; Feldman L, Brown C, Badie B. Chimeric antigen receptor (CAR) T cell therapy for glioblastoma. Neuromolecular Med. 2022; 2021: 1-6. doi:10.1007/s12017-021-08689-5; Yoo HJ, Harapan BN. Chimeric antigen receptor (CAR) immunotherapy: Basic principles, current advances, and future prospects in neuro-oncology. Immunologic Res. 2021; 69(6): 471- 486. doi:10.1007/s12026-021-09236-x; Fu W, Wang W, Li H, Jiao Y, Huo R, Yan Z, et al. Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma. Front Immunol. 2020; 11: 835. doi:10.3389/fimmu.2020.00835; Shen SH, Woroniecka K, Barbour AB, Fecci PE, SanchezPerez L, Sampson JH, et al. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther. 2020; 20(6): 579-591. doi:10.1080/14712598.2020.1727436; Xiong Q, Zhu J, Zhang Y, Deng H. CAR-NK cell therapy for glioblastoma: What to do next? Front Oncol. 2023; 13: 1192128. doi:10.3389/fonc.2023.1192128; Stavrakaki E, Dirven CMF, Lamfers MLM. Personalizing oncolytic virotherapy for glioblastoma: In search of biomarkers for response. Cancers (Basel). 2021; 13(4): 614. doi:10.3390/cancers13040614; Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021; 21(6): 360-378. doi:10.1038/s41568-021-00346-0 10. ter Haar G. The history of focused ultrasound. URL: https://www.fusfoundation.org/posts/the-history-of-focused-ultrasound [date of access: 11.03.2021].; Лаборатория медицинского и промышленного ультразвука. URL: http://limu.msu.ru [дата доступа: 1.11.2023].; Назаренко Г.И., Чен В.Ш., Джан Л., Хитрова А.Н., Пащенко Н.В. Ультразвуковая абляция как высокотехнологичная органосохраняющая альтернатива хирургической операции. URL: https://oncology.ru/specialist/journal_oncology/archive/0209/018.pdf [дата доступа: 31.10.2023].; Yang Q, Zhou Y, Chen J, Huang N, Wang Z, Cheng Y. Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. IntJ Nanomedicine. 2021; 16: 185-199. doi:10.2147/IJN.S286221; Zheng Q, Xia B, Huang X, Luo J, Zhong S, Li X. Nanomedicines for high intensity focused ultrasound cancer treatment and theranostics (review). Exp Ther Med. 2023; 25(4): 170. doi:10.3892/etm.2023.11869; Пономарчук Е.М., Буравков С.В., Ванг Я.Н, Хохлова Т.Д., Хохлова В.А. Морфологический анализ разрушений биологической ткани при облучении мощными фокусированными ультразвуковыми импульсами с ударными фронтами. Ученые записки физического факультета МГУ. 2016; 4: 164701; Lamsam L, Johnson E, Connolly ID, Wintermark M, Hayden Gephart M. A review of potential applications of MRguided focused ultrasound for targeting brain tumor therapy. Neurosurg Focus. 2018; 44(2): 10. doi:10.3171/2017.11.FOCUS17620; Roberts JW, Powlovich L, Sheybani N, LeBlang S. Focused ultrasound for the treatment of glioblastoma. J Neurooncol. 2022; 157(2): 237-247. doi:10.1007/s11060-022-03974-0; Галимова Р.М., Иллариошкин С.Н., Бузаев И.В., Качемаева О.В. Терапия двигательных нарушений методом фокусированного ультразвука под контролем магнитно-резонансной томографии. Рекомендации для врачей-неврологов по отбору пациентов. Новые технологии. 2020; 1: 9-15. doi:10.24411/2226-079X-2020-12168; Janwadkar R, Leblang S, Ghanouni P, Brenner J, Ragheb J, Hennekens CH, et al. Focused ultrasound for pediatric diseases. Pediatrics. 2022; 149(3): e2021052714. doi:10.1542/peds.2021-05271; Москвичева Л.И. Применение HIFU-терапии в онкологии (2000–2021 гг.). Онкология. Журнал им. П.А. Герцена. 2022; 11(1): 64-74. doi:10.17116/onkolog20221101164; Bachu VS, Kedda J, Suk I, Green JJ, Tyler B. High-intensity focused ultrasound: A review of mechanisms and clinical applications. Ann Biomed Eng. 2021; 49(9): 1975-1991. doi:10.1007/s10439-021-02833-9; Галкин М.В. Применение транскраниального фокусированного ультразвука в лечении патологии ЦНС. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко. 2016; 80(2): 108-118. doi:10.17116/neiro2016802108-118; Paun L, Moiraghi A, Jannelli G, Nouri A, DiMeco F, Pallud J, et al. From focused ultrasound tumor ablation to brain blood barrier opening for high grade glioma: A systematic review. Cancers (Basel). 2021; 13(22): 5614. doi:10.3390/cancers13225614; Duryea AP, Hall TL, Maxwel AD, Zhen X, Cain CA, et al. Histotripsy erosion of model urinary calculi. J Endourol. 2011; 25(2): 341-344. doi:10.1089/end.2010.0407; Sukovich JR, Cain CA, Pandey AS, Chaudhary N, CameloPiragua S, Allen SP, et al. In vivo histotripsy brain treatment. J Neurosurg. 2018; 131(4): 1-8. doi:10.3171/2018.4.JNS172652; Choi SW, Duclos S, Camelo-Piragua S, Chaudhary N, Sukovich J, Hall T, et al. Histotripsy treatment of murine brain and glioma: Temporal profile of magnetic resonance imaging and histological characteristics post-treatment. Ultrasound Med Biol. 2023; S0301- 5629(23)00148-5. doi:10.1016/j.ultrasmedbio.2023.05.002; Hendricks-Wenger A, Hutchison R, Vlaisavljevich E, Allen IC. Immunological effects of histotripsy for cancer therapy. Front Oncol. 2021; 11: 681629. doi:10.3389/fonc.2021.681629; Deligne C, Hachani J, Duban-Deweer S, Meignan S, Leblond P, Carcaboso AM, et al. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS. 2020; 17: 37. doi:10.1186/s12987-020-00198-0; Angeli E, Nguyen TT, Janin A, Bousquet G. How to make anticancer drugs cross the blood-brain barrier to treat brain metastases. Int J Mol Sci. 2019; 21(1): 22. doi:10.3390/ijms21010022; Воропаева Е.Н., Карпова В.С., Поспелова Т.И., Максимов В.Н., Воронцова Е.В. Современные представления о роли гематоэнцефалического барьера в развитии лимфом центральной нервной системы. Journal of Siberian Medical Sciences. 2022; (2): 131-147. doi:10.31549/2542-1174-2022-6-2-131-147; Brighi C, Reid L, White AL, Genovesi LA, Kojic M, Millar A, et al. MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma. Neurooncol Adv. 2020; 2(1): vdaa030. doi:10.1093/noajnl/vdaa030; Bunevicius A, McDannold NJ, Golby AJ. Focused ultrasound strategies for brain tumor therapy. Oper Neurosurg (Hagerstown). 2020; 19(1): 9-18. doi:10.1093/ons/opz374; Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: Potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009; 15: 7092-7098. doi:10.1158/1078-0432.CCR-09-1349; Bérard C, Truillet C, Larrat B, Dhermain F, Estève MA, Correard F, et al. Anticancer drug delivery by focused ultrasoundmediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside. Pharmacol Ther. 2023; 250: 108518. doi:10.1016/j.pharmthera.2023.108518; Alli S, Figueiredo CA, Golbourn B, Sabha N, Wu MY, Bondoc A, et al. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery. J Control Release. 2018; 281: 29-41. doi:10.1016/j. jconrel.2018.05.005; van Vuurden. Van Vuurden group. The Princess Maxima Center. URL: https://research.prinsesmaximacentrum.nl/en/research-groups/van-vuurden-group [date of access: 31.10.2023].; t’ Hart E, Bianco J, Bruin MAC, Derieppe M, Besse HC, Berkhout K, et al. Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. J Control Release. 2023; 357: 287-298. doi:10.1016/j.jconrel.2023.03.058; Mittelstein DR, Ye Jian, Schibber EF, Roychoudhury A, Martinez LT, Fekrazad MH, Ortiz M, et al. Selective ablation of cancer cells with low intensity pulsed ultrasound. Appl Phys Lett. 2020; 116(1): 013701 doi:10.1063/1.5128627; Zhu L, Altman MB, Laszlo A, Straube W, Zoberi I, Hallahan Dennis E, et al. Ultrasound hyperthermia technology for radiosensitization. Ultrasound Med Biol. 2019; 45: 1025-1043. doi:10.1016/j.ultrasmedbio.2018.12.007; Schneider CS, Woodworth GF, Vujaskovic Z, Mishra MV. Radiosensitization of high-grade gliomas through induced hyperthermia: Review of clinical experience and the potential role of MR-guided focused ultrasound. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020; 142: 43-51. doi:10.1016/j.radonc.2019.07.017; D’Ammando A, Raspagliesi L, Gionso M, Franzini A, Porto E, Di Meco F, et al. Sonodynamic therapy for the treatment of intracranial gliomas. J Clin Med. 2021; 10(5): 1101. doi:10.3390/jcm10051101; Choi V, Rajora MA, Zheng G. Activating drugs with sound: mechanisms behind sonodynamic therapy and the role of nanomedicine. Bioconjugate Chemistry. 2020; 31(4): 967-989.; Venter RL. Effects of low intensity bio-resonance focused ultrasound on destroying cancerous cells: A literature review of low intensity bio-resonance focused on destroying cells. IAJPS. 2021; 08(05): 125-144. doi:10.5281/zenodo.4752632; Meng Y, Pople CB, Suppiah S, Llinas M, Huang Y, Sahgal A, et al. MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors. Neuro Oncol. 2021; 23(10): 1789-1797. doi:10.1093/neuonc/noab057; Zhu L, Nazeri A, Pacia CP, Yue Y, Chen H. Focused ultrasound for safe and effective release of brain tumor biomarkers into the peripheral circulation. PLoS One. 2020; 15(6): e0234182. doi:10.1371/journal.pone.0234182; Pacia CP, Zhu L, Yang Y, Yue Y, Nazeri A, Gach M, et al. Feasibility and safety of focused ultrasound-enabled liquid biopsy in the brain of a porcine model. Sci Rep. 2020; 10(1):7449. doi:10.1038/s41598-020-64440-3; https://www.actabiomedica.ru/jour/article/view/4603
Processing Request
No Comments.